Faculty Profiles - MORI KAZUYUKI

Papers - MORI KAZUYUKI

Division display1 - 20 of about 45／ All the affair displays >>

Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.

Mori K, Hatakeyama S, Enokida H, Miyake H, Kikuchi E, Nishiyama H, Ichikawa T, Kamai T, Kaji Y, Kume H, Kondo T, Matsuyama H, Masumori N, Kawauchi A, Takenaka A, Uemura H, Eto M, Nonomura N, Fujii Y, Hinotsu S, Ohyama C.

Int J Urol 31 ( 3 ) 194 - 207 2024.3

Humoral response to SARS-CoV-2 mRNA vaccine on in ABO blood type incompatible kidney transplant recipients treated with low-dose rituximab.

Hamaya T, Hatakeyama S, Yoneyama T, Tobisawa Y, Kodama H, Fujita T, Murakami R, Mori K, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Saitoh H, Narumi S, Tomita H, Ohyama C.

Sci Rep 13 ( 1 ) 15098 2023.9

Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.

Okuyama Y, Hatakeyama S, Tabata R, Fujimori D, Kawashima Y, Tanaka T, Fujita N, Okamoto T, Mori K, Yamamoto H, Yoneyama T, Hashimoto Y, Matsuoka T, Sato S, Ohyama C.

Int J Urol 30 ( 8 ) 649 - 657 2023.8

Altered gut microbiome associated with overactive bladder and daily urinary urgency.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol 39 ( 3 ) 847 - 853 2021.3

N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.

Kodama H, Yoneyama T, Tanaka T, Noro D, Tobisawa Y, Yamamoto H, Suto S, Hatakeyama S, Mori K, Yoneyama T, Hashimoto Y, Kakizaki I, Nakaji S, Ohyama C.

Cancer Med 10 ( 4 ) 1297 - 1313 2021.2

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol 39 ( 1 ) 169 - 175 2021.1

The association between gut microbiome and erectile dysfunction: a community- based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

Int Urol Nephrol 52 ( 8 ) 1421 - 1428 2020.8

The association between gut microbiome and erectile dysfunction: a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

Int Urol Nephrol 2020.3

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan.

Okamoto T, Hatakeyama S, Imai A, Yamamoto H, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

World J Urol 2020.3

Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma.

Suppanuntaroek S, Hatakeyama S, Fujita N, Kubota Y, Suzuki Y, Okamoto T, Tobisawa Y, Yoneyama T, Yamamoto H, Mori K, Imai A, Yoneyama T, Hashimoto Y, Ohyama C.

Int J Clin Oncol. 25 ( 2 ) 362 - 369 2020.3

The Relationship Between Gait Function and Erectile Dysfunction: Results from a Community-Based Cross-Sectional Study in Japan.

Okamoto T, Hatakeyama S, Imai A, Konishi S, Okita K, Yamamoto H, Tobisawa Y, Yoneyama T, Mori K, Yoneyama T, Hashimoto Y, Nakaji S, Ohyama C.

J Sex Med. 16 ( 12 ) 1922 - 1929 2019.12

Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection.

Yoneyama T, Tobisawa Y, Kaneko T, Kaya T, Hatakeyama S, Mori K, Sutoh Yoneyama M, Okubo T, Mitsuzuka K, Duivenvoorden W, Pinthus JH, Hashimoto Y, Ito A, Koie T, Suda Y, Gardiner RA, Ohyama C.

Cancer Sci. 110 ( 8 ) 2573 - 2589 2019.8

KK47細胞BCG生菌耐性株に対するナノパーティクルBCGの直接効果と耐性株の遺伝子発現解析

盛　和行、米山　徹、小玉　寛健、日下　歩、細越　正吾、得居　範子、山本　勇人、今井　篤、畠山　真吾、米山　高弘、橋本　安弘、古家　琢也、大山　力

泌尿器外科 31 ( 4 ) 401 - 402 2018.4

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas.

Tanaka T, Yoneyama T, Noro D, Imanishi K, Kojima Y, Hatakeyama S, Tobisawa Y, Mori K, Yamamoto H, Imai A, Yoneyama T, Hashimoto Y, Koie T, Tanaka M, Nishimura SI, Kurauchi S, Takahashi I, Ohyama C.

Int J Mol Sci. 18 ( 12 ) 2632 - 2644 2017.12

BCG関連新規薬物療法の開発

盛　和行

日本臨床 75 ( Suppl 7 ) 319 - 322 2017.10

Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant.

Noro D, Yoneyama T, Hatakeyama S, Tobisawa Y, Mori K, Hashimoto Y, Koie T, Tanaka M, Nishimura SI, Sasaki H, Saito M, Harada H, Chikaraishi T, Ishida H, Tanabe K, Satoh S, Ohyama C.

Int J Mol Sci. 18 ( 8 ) 1731 - 1747 2017.8

BCG生菌double耐性株に対するナノパーティクルBCGの直接効果

盛　和行, 米山　徹, 野呂　大輔, 成田　拓磨, 田中　壽和, 萩原　和久, 及川　真亮, 今井　篤, 畠山　真吾, 米山　高弘, 橋本　安弘, 古家　琢也, 大山　力

泌尿器外科 30 ( 4 ) 442 - 443 2017.4

糖鎖を標的にした前立腺癌バイオマーカーの開発と臨床応用

大山　力，米山　徹，飛澤　悠葵，石川　友一，畠山　真吾，古家　琢也，盛　和行

臨床病理 65 ( 2 ) 210 - 217 2017.2

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer

Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Suda Y, Ohyama C, Yoneyama T

Int J Mol Sci 18 ( 2 ) 261 - 276 2017.1

Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness

Sato T, Yoneyama T, Tobisawa Y, Hatakeyama S, Yamamoto H, Kojima Y, Mikami J, Mori K, Hashimoto Y, Koie T, Ohyama C

Biochem Biophys Res Commun 2016.1

　PREV- NEXT 　

1
2
3